Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. Moslehi JJ, Deininger M (2015) J Clin Oncol 33: 4210-8 LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer. Schwarz LJ, Fox EM, Balko JM, Garrett JT, Kuba MG, Estrada MV, González-Angulo AM, Mills GB, Red-Brewer M, Mayer IA, Abramson V, Rizzo M, Kelley MC, Meszoely IM, Arteaga CL (2014) J Clin Invest 124: 5490-502 Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE (2009) Cancer Res 69: 3842-9 Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, Gelovani JG, Kim SJ, Wang Z, Gallick GE (2008) Cancer Res 68: 3323-33 Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth. Nagaraj NS, Washington MK, Merchant NB (2011) Clin Cancer Res 17: 483-93 Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth. Yeung CL, Ngo VN, Grohar PJ, Arnaldez FI, Asante A, Wan X, Khan J, Hewitt SM, Khanna C, Staudt LM, Helman LJ (2013) Oncogene 32: 5429-38 Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Nagaraj NS, Smith JJ, Revetta F, Washington MK, Merchant NB (2010) Mol Cancer Ther 9: 2322-32 Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib. Johnson ML, Riely GJ, Rizvi NA, Azzoli CG, Kris MG, Sima CS, Ginsberg MS, Pao W, Miller VA (2011) J Thorac Oncol 6: 1128-31 Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer. Dosch AR, Dai X, Reyzer ML, Mehra S, Srinivasan S, Willobee BA, Kwon D, Kashikar N, Caprioli R, Merchant NB, Nagathihalli NS (2020) Mol Cancer Res 18: 623-631 Global phosphotyrosine proteomics identifies PKCδ as a marker of responsiveness to Src inhibition in colorectal cancer. McKinley ET, Liu H, McDonald WH, Luo W, Zhao P, Coffey RJ, Hanks SK, Manning HC (2013) PLoS One 8: e80207
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.